Ramatroban (Baynas): a review of its pharmacological and clinical profile.

DOI Web Site Web Site PubMed 1 Citations 18 References

Bibliographic Information

Other Title
  • トロンボキサンＡ２受容体きっ抗薬（ラマトロバン：バイナス錠）の薬理学特性と臨床効果
  • 新薬紹介総説 トロンボキサンA2受容体拮抗薬(ラマトロバン:バイナス錠)の薬理学特性と臨床効果
  • シンヤク ショウカイ ソウセツ トロンボキサン A2 ジュヨウタイ キッコウヤク ラマトロバン バイナスジョウ ノ ヤクリガク トクセイ ト リンショウ コウカ

Search this article

Abstract

Bayer has been interested in the observations that metabolites of arachidonic acid are involved in allergy and inflammation. Ramatroban was thus developed as a therapeutic agent for allergic and inflammatory diseases. Ramatroban showed an antagonistic action on the thromboxane A2 (TXA2) receptor in in vitro experiments using platelets or arteries. It inhibited the permeability of capillary and also the infiltration of eosinophils in nasal mucosa. Ramatroban had an inhibitory effect on the nasal resistance stimulated by either U-46619 or antigen challenge in in vivo experiments. The concentration of nasal TXA2 was increased when the antigen was challenged to allergic patients. Clinical trials demonstrated that ramatroban decreased sneezing, rhinorrhea, and rhinostenosis in patients enrolled in the study. No serious adverse reaction of ramatroban was observed in patients throughout the trials. The treatment with ramatroban is safe and improves nasal symptoms.

Journal

Citations (1)*help

See more

References(18)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top